Cytokinetics Inc vs EOG Resources Inc — how do they compare? Cytokinetics Inc trades at $77.67 (market cap $10.78B), while EOG Resources Inc trades at $143.02 (market cap $74.60B). The key difference: EOG Resources Inc is far larger — about 6.9× Cytokinetics Inc's market cap, and EOG Resources Inc pays a 2.87% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | EOG | |
|---|---|---|
Market Cap | $10.78B | $74.60B |
Sector | Technology | Energy |
52-Week High | $87.26 | $149.89 |
52-Week Low | $33.23 | $101.78 |
Enterprise Value | $10.88B | $77.94B |
Dividend Yield | — | 2.87% |
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
EOG Resources trades at $134.74, down 1.07% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $5.07, beating estimates, with revenue growth driven by higher oil prices and production. Valuation metrics remain attractive with P/E of 10.49 and EV/EBITDA of 5.32, while maintaining robust profitability with 25.81% net margin and 22.51% ROE.
EOG presents a compelling value opportunity with strong earnings momentum and shareholder returns through dividends. However, negative cash flow trends and energy price volatility pose near-term risks. Analyst consensus remains bullish with $162.11 price target, representing 20% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →